Ulcerative colitis-associated colorectal cancer

The association between ulcerative colitis(UC) and colorectal cancer(CRC) has been acknowledged. One of the most serious and life threatening consequences of UC is the development of CRC(UC-CRC). UC-CRC patients are younger, more frequently have multiple cancerous lesions, and histologically show mu...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 44; pp. 16389 - 16397
Main Author Yashiro, Masakazu
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.11.2014
Subjects
Online AccessGet full text
ISSN1007-9327
2219-2840
2219-2840
DOI10.3748/wjg.v20.i44.16389

Cover

Loading…
More Information
Summary:The association between ulcerative colitis(UC) and colorectal cancer(CRC) has been acknowledged. One of the most serious and life threatening consequences of UC is the development of CRC(UC-CRC). UC-CRC patients are younger, more frequently have multiple cancerous lesions, and histologically show mucinous or signet ring cell carcinomas. The risk of CRC begins to increase 8 or 10 years after the diagnosis of UC. Risk factors for CRC with UC patients include young age at diagnosis, longer duration, greater anatomical extent of colonic involvement, the degree of inflammation, family history of CRC, and presence of primary sclerosing cholangitis. CRC on the ground of UC develop from non-dysplastic mucosa to indefinite dysplasia, lowgrade dysplasia, high-grade dysplasia and finally to invasive adenocarcinoma. Colonoscopy surveillance programs are recommended to reduce the risk of CRC and mortality in UC. Genetic alterations might play a role in the development of UC-CRC. 5-aminosalicylates might represent a favorable therapeutic option for chemoprevention of CRC.
Bibliography:Masakazu Yashiro;Department of Surgical Oncology, Osaka City University Graduate School of Medicine;Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Correspondence to: Masakazu Yashiro, MD, PhD, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp
Telephone: +81-6-66453838 Fax: +81-6-66466450
Author contributions: Yashiro M solely contributed to the manuscript.
ISSN:1007-9327
2219-2840
2219-2840
DOI:10.3748/wjg.v20.i44.16389